Register
Login:
Share:
Email Facebook Twitter


Ariana forecast 47% rise in Kiziltepe gold production


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 44.00Bid: 43.10Ask: 43.40Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 0.30Spread as %: 0.70%Open: 37.10High: 50.00Low: 37.10Yesterday’s Close: 44.00

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
44.00
Share Price SpacerBid
43.10
Share Price SpacerAsk
43.40
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
17,028,717
Share Price SpacerOpen
37.10
Share Price SpacerHigh
50.00
Share Price SpacerLow
37.10
Share Price SpacerClose
44.00
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 139.47m £61.37m 3,000

52 Week High 193.00 52 Week High Date 4-JAN-2018
52 Week Low 19.00 52 Week Low Date 17-APR-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1,882 5,932,943 8,954,587 -9.692 -4.54 0.00 0.00


London South East Users info for Immupharma




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

20-Apr-18
18:38:15
43.998
5,804
Buy* 
43.10
43.40
2,554
Trade Type:
Ordinary

20-Apr-18
16:52:23
45.1273
93,199
Buy* 
43.10
43.40
42.06k
Trade Type:
Ordinary
Delayed publication

20-Apr-18
16:52:09
43.5957
292,171
Buy* 
43.10
43.40
127.37k
Trade Type:
Ordinary
Delayed publication




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Today 11:12WisheyedbortumWeb MD.44.00No Opinion
Just read a few reviews about Benylista on WebMD and you have to feel very sorry for the folk who are stuck with lupus and the pain and side effects that they are suffering. You also have to feel sorry for them that Lupusor was not allowed onto the market. Perhaps they should collaborate and demand it. And yes, I am one of the "suckers" that gambled and at this point in time have lost, but that can't be the end of the story, not if you read WebMD.
Today 10:06SCC06RE: Investor 2018 london44.00No Opinion
I can see news on big pharma interest very soon. Why say it otherwise. The bottom line is the drug is safer than the market leader and more efficacious, with all the negativity surrounding this phase 3 it's a miracle benylista was granted approval but wtfdik
Today 09:01hamila01RE: Investor 2018 london44.00No Opinion
Why do you suggest that IPad?
Today 06:38IpadRE: Investor 2018 london44.00No Opinion
Big announcement coming imho.
Today 04:22PsyurmhRE: Huge drop44.00No Opinion
I think he is the “sucker” on that evidence!
Today 04:22PsyurmhRE: Huge drop44.00Buy
Crack sold at 8:44 on Thursday at 35.5p and was hoping for 26p. Probably upset we are have surged to 40s and 50s!!

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.